Marc Massanari

Summary

Affiliation: Novartis Institutes for BioMedical Research

Publications

  1. ncbi Efficacy of omalizumab in cat-allergic patients with moderate-to-severe persistent asthma
    Marc Massanari
    Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936 1080, USA
    Allergy Asthma Proc 30:534-9. 2009
  2. ncbi Adding omalizumab to the therapy of adolescents with persistent uncontrolled moderate--severe allergic asthma
    M Massanari
    Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936 1080, USA
    Clin Pediatr (Phila) 48:859-65. 2009
  3. ncbi Effect of omalizumab on peripheral blood eosinophilia in allergic asthma
    M Massanari
    Novartis Pharmaceuticals Corp, East Hanover, NJ 07936 1080, USA
    Respir Med 104:188-96. 2010
  4. ncbi Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma
    Marc Massanari
    Novartis Pharmaceuticals Corp, East Hanover, NJ 07936 1080, USA
    J Allergy Clin Immunol 125:383-9. 2010

Detail Information

Publications4

  1. ncbi Efficacy of omalizumab in cat-allergic patients with moderate-to-severe persistent asthma
    Marc Massanari
    Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936 1080, USA
    Allergy Asthma Proc 30:534-9. 2009
    ..Omalizumab improved asthma control by reducing exacerbations and decreasing symptoms in cat-allergic patients with moderate-to-severe persistent IgE-mediated asthma...
  2. ncbi Adding omalizumab to the therapy of adolescents with persistent uncontrolled moderate--severe allergic asthma
    M Massanari
    Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936 1080, USA
    Clin Pediatr (Phila) 48:859-65. 2009
    ..This study aimed to evaluate the effectiveness of omalizumab among adolescents with moderate-severe allergic asthma inadequately controlled with inhaled corticosteroids...
  3. ncbi Effect of omalizumab on peripheral blood eosinophilia in allergic asthma
    M Massanari
    Novartis Pharmaceuticals Corp, East Hanover, NJ 07936 1080, USA
    Respir Med 104:188-96. 2010
    ..The findings from our analysis of a large patient population are consistent with earlier reports of the inhibitory effect of omalizumab on eosinophils...
  4. ncbi Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma
    Marc Massanari
    Novartis Pharmaceuticals Corp, East Hanover, NJ 07936 1080, USA
    J Allergy Clin Immunol 125:383-9. 2010
    ..Although specific immunotherapy is a valuable treatment option for patients with allergic asthma, the potential for systemic allergic reactions has limited its use, especially for patients with symptomatic disease...